Raising Health Adapting Biopharma to AI: A 2024 Update with Greg Meyers
Aug 27, 2024
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, joins Jorge Conde of a16z to discuss the rapidly evolving role of AI in biopharma. They explore how technology serves as a competitive advantage and delve into generative AI's impact on drug development, particularly in cancer treatments. The conversation highlights the importance of agile partnerships in innovation and addresses the challenges of integrating AI into regulated healthcare, emphasizing the need for responsible practices and effective data management.
AI Snips
Chapters
Transcript
Episode notes
AI's Broad Impact In Pharma
- AI is transforming the pharmaceutical pipeline in drug discovery, clinical trials, clinician interface, and digital health products.
- AI enables molecule design improvements, accelerates clinical trials, and enhances disease diagnosis and treatment.
From AI Pilots To Transformation
- Move beyond pilots to reimagine complex business processes with AI for real impact.
- Validate AI trustworthiness by ensuring data quality and understanding biases thoroughly.
Effective AI Strategy Principles
- Be humble, nimble, and decisive when devising AI strategies to adapt to rapid innovation.
- Avoid lengthy partnerships; prioritize agility to incorporate new AI advancements quickly.